Individuals who were positive for anti-EBNA-1 IgA at baseline experienced higher rates of NPC during follow-up than those testing negative (relative risk = 6.6, 95% confidence interval (CI): 1.5–61) [58]. The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.